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The Signaling Lymphocyte Activation Molecule Family (SLAMF ) genes, which encode
cell-surface receptors that modulate innate and adaptive immune responses, lay within
a genomic region of human and mouse chromosome 1 that confers a predisposition
for the development of systemic lupus erythematosus (SLE). Herein, we demonstrate
that the SLAMF member Ly9 arises as a novel receptor contributing to the reinforce-
ment of tolerance. Specifically, Ly9-deficient mice spontaneously developed features
of systemic autoimmunity such as the production of anti-nuclear antibodies (ANA),
-dsDNA, and -nucleosome autoantibodies, independently of genetic background [(B6.129)
or (BALB/c.129)]. In aged (10- to 12-month-old) Ly9−/− mice key cell subsets implicated
in autoimmunity were expanded, e.g., T follicular helper (Tfh) as well as germinal center
(GC) B cells. More importantly, in vitro functional experiments showed that Ly9 acts as
an inhibitory receptor of IFN-γ producing CD4+ T cells. Taken together, our findings reveal
that the Ly9 receptor triggers cell intrinsic safeguarding mechanisms to prevent a breach
of tolerance, emerging as a new non-redundant inhibitory cell-surface receptor capable of
disabling autoantibody responses.
Keywords: SLAMF, Ly9 (CD229, SLAMF3), anti-DNA autoantibodies, disease susceptibility, systemic lupus erythe-
matosus, murine Lupus
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disease characterized by major immunological stigmata,
the production of antibodies against own cellular nuclear compo-
nents. The mechanisms underlying SLE are complex and include
genetic, epigenetic, environmental, hormonal, and immunoregu-
latory factors. Furthermore, multiple pathogenic pathways likely
contribute to end-organ damage in this heterogeneous disease (1–
3). Elucidation of these pathways, as well as the identification of
new molecular disease markers and targets that account for the
pathogenesis of lupus, are crucial to improve currently available
therapeutic approaches.
Genetic predisposition is a central factor to the development
of SLE (4, 5). Both Genome Wide Association studies (GWAS)
and the in depth analyses of genetically altered and congenic
mice have provided insights into the genetic control of lupus. For
instance, mouse strains bearing either a NZW- or 129-derived
genomic segment that is embedded in chromosome 1 of B6
mice, develop a lupus-like disease due to the epistatic interactions
between the 129-derived genes and B6 genes (6). Analysis of con-
genic NZW×B6 mice identified the Sle1 region of chromosome
1 and its subregions Sle1a, -b, and -c, as key elements involved
in breaching B- and T-cell tolerance to chromatin, an essential
early step leading to full-blown onset of the disease. Remark-
ably, multiple gene-wide linkage scans in SLE families have also
identified a syngenic lupus susceptibility locus (region 1q23) in
human chromosome 1 (7, 8).
Precise mapping of the Sle1 region identified a gene interval
of 0.9 Mb, termed Sle1b, as the most potent segment involved
in the generation of autoantibodies. Interestingly, this segment
includes seven signaling lymphocyte activation molecule family
(SLAMF) cell-surface receptor genes (9). The proteins encoded by
these genes are the best suited candidates for controlling signal-
ing pathways in Sle1 tolerance due to their extensive polymorphic
nature and isoform diversity, coupled with their ability to modu-
late innate and adaptive immunity (10, 11). The SLAMF receptors
(SLAMF1–9) are involved in the functional regulation of several
immune cell types, including helper and cytotoxic T lympho-
cytes, NK cells, and macrophages (12–15). These receptors mediate
adhesion and regulate cognate T-cell–B-cell interactions, which
elicit signal transduction by recruiting SLAM-associated protein
(SAP). Importantly, SAP deficiency selectively impairs the ability
of CD4+ T cells to stably interact with cognate B cells, avoid-
ing differentiation toward T follicular helper cells (Tfh), and the
generation of T-dependent B-cell responses (16–18). Consistent
with this role, the absence of SAP mitigates autoimmunity in
various mouse models of lupus by disrupting the generation of
germinal centers (GC) (19, 20). Increasing evidence suggests that
a defective response to self-antigens in the periphery can consti-
tute a relevant pathogenic event. More specifically, autoantibodies
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detected in lupus patients and lupus-prone mice had suffered
isotype switching and somatic hypermutation, which facilitated
the binding to self-antigens with high affinity, all indicating the
involvement of GC pathways in this disease (21, 22). This, there-
fore, provides a rational for determining not only the exact role
played by SLAMF receptors as key drivers of Tfh and GC forma-
tion, but also their potential as appealing therapeutic targets for
autoantibody-mediated diseases.
While recent reports have identified Slamf6 (Ly108) receptor
and its isoforms and Slamf2 (2B4) as contributing to the role
played by Sle1b in tolerance (23–25), the involvement of other
SLAMF members cannot be excluded. Of particular interest is
the Ly9 (CD229, Slamf3) molecule, since a comparative analy-
sis between B6 and the autoimmune congenic strain B6.Sle1b
revealed significant differences in its isoforms usage, as well as
in the extent of polymorphisms and expression levels (9), with the
evidence indicating the possible participation of Ly9 in B6.Sle1b
autoimmunity. Briefly, Ly9 expression is restricted to hematopoi-
etic cells, including B and T lymphocytes (26). As has been shown
in other SLAMF members, Ly9 functions as a homophilic adhesion
receptor and its cytoplasmic tail contains two copies of the con-
served tyrosine-based switch motif (ITSM), which is a docking site
for the adapter molecules SAP and EAT-2 (27, 28). Ly9-deficient
mice with a mixed 129×B6 background exhibited no major T-cell
developmental abnormalities and only very mild defects in T-cell
responses (29). Recent findings demonstrate the role of Ly9 as a
unique inhibitory cell-surface receptor regulating the size of the
thymic innate CD8+ T-cell pool and the development of invariant
Natural Killer T (iNKT) cells (30). Nonetheless, the functional
role of Ly9 in lupus pathogenesis remains unknown. Here, we
use Ly9-deficient mice, which were generated with 129-derived ES
cells and then backcrossed onto B6 or BALB/c backgrounds, in
order to determine the role of the Ly9 receptor in autoantibody
development.
MATERIALS AND METHODS
MICE
Ly9−/−mice (129×B6), generously provided by Dr. McKean (29),
were backcrossed onto BALB/c background for 12 generations to
generate the Ly9−/−(BALB/c.129) strain and onto C57BL/6 (B6)
background for 12 generations to generate the Ly9−/−(B6.129)
strain. Eight-week-old BALB/c and B6 wild-type mice were pur-
chased from Charles River Laboratories (Saint-Aubin-lès-Elbeuf,
France). All mice strains were maintained under specific pathogen-
free (SPF) conditions for up to 12 months. Serum samples were
collected from the tail vein at 3-, 6-, 9-, and 12-months of age.
At 12 months, mice were euthanized, a peritoneal lavage was car-
ried out and kidneys, bone marrow, spleen, thymus, and sera
were harvested. Experiments were conducted in compliance with
institutional guidelines as well as with national laws and policies.
ANTI-NUCLEAR ANTIBODIES ANALYSIS
Anti-nuclear antibodies (ANA) titers were determined by indi-
rect immunofluorescence using permeabilized Hep-2 cells. Serum
samples were progressively diluted and incubated for 1 h at room
temperature on Hep-2 cells followed by Texas Red-conjugated
anti-mouse IgG (Jackson Laboratory, Bar Harbor). After washing,
the nucleus was stained with 4′,6-diamidino-2-phenylindole
(DAPI). Analysis was performed by fluorescence detection using a
Nikon Eclipse fluorescent microscope (Nikon, Tokyo).
ANTI-DOUBLE-STRANDED DNA AND ANTI-CHROMATIN DETECTION
ELISA assays were performed to quantify levels of anti-double-
stranded DNA (anti-dsDNA) and anti-chromatin antibodies in
sera of mice. For anti-dsDNA detection, an ELISA was carried out
using heat-denatured calf thymus DNA (Sigma Chemical Co., St
Louis, MO, USA). dsDNA was coated onto 96-well plates (Corn-
ing Costar, Corning, NY, USA) at 10µg/ml. Purified antibody
anti-dsDNA (Clone HpS22, Immunotools, Friesoythe, Germany),
used as standard, was serially diluted. Standards and test serums
(dilution 1:100) were incubated on plates for 1 h at room tempera-
ture. After extensive washing, autoantibodies were detected using a
HRP-conjugated anti-mouse IgG (Sigma-Aldrich) and developed
with OPD substrate (Sigma-Aldrich).
Anti-chromatin autoantibodies were detected using nucle-
osome antigen (Arotec Diagnostics Limited, Wellington, New
Zealand). The nucleosome antigen was coated on 96-well plates at
3µg/ml. Serums were diluted 1:100 and incubated for 1 h at room
temperature. Autoantibodies against nucleosome were detected
using a HRP-conjugated anti-mouse IgG and developed with sub-
strate. All samples were handled simultaneously under the same
experimental conditions and results are expressed as OD values.
IgG ISOTYPE DETECTION
Basal serum IgG isotypes were determined by ELISA using puri-
fied goat anti-mouse IgG (Sigma-Aldrich) coated 96-well plates.
1:100 diluted mouse serums were incubated for 1 h at room tem-
perature. After extensive washing, IgG isotypes were detected using
biotin-conjugated anti-mouse IgG1, IgG2a, IgG2b, and IgG3 (Jack-
son Laboratory). All samples were handled simultaneously under
the same experimental conditions and results are expressed as OD
values.
FLOW CYTOMETRY
Single-cell suspensions were incubated with 20% heat-inactivated
rabbit serum before being stained on ice with fluorophore-
labeled antibodies against surface molecules using standard meth-
ods. Data was acquired using a FACSCanto II (BD Pharmin-
gen, San Jose, CA, USA) flow cytometer and analyzed with
either FACSDiva™ (BD Pharmingen) or FlowJo software (Tree
Star, San Carlos, CA, USA). The following anti-mouse mAbs
were obtained from BD Pharmingen: CD4-FITC, CD11b-PE,
CD21-FITC, CD23-FITC, CD24-FITC, CD43-FITC, CD44-FITC,
CD62L-FITC, CD69-FITC, CD154-PE, c-Kit-PE, Ter-119-PE,
IgM-biotinylated, and CXCR5-biotinylated. The mAbs CD8-
FITC, CD11b-FITC, CD25-PE, CD25-FITC, IgM-FITC, B220-
FITC, as well as the isotype-matched control Abs, were acquired
from ImmunoTools (Friesoythe, Germany). The following mAbs
were obtained from BioLegend (San Diego, CA, USA): CD3-
FITC, CD4-Pacific Blue, CD8-PE-Cy5, PD1-PE, PD1-PE-Cy7,
B220-Pacific Blue, CD41-FITC, and IgD-APC-Cy7. The mAbs
CD3-APC, CD5 PE-Cy7, CD229-APC, Sca-1-APC, and GL-7-
FITC were purchased from eBioscience (San Diego, CA, USA).
Anti-mouse CD138-APC was obtained from R&D Biosystems
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(R&D System, Wiesbaden, Germany). R-PE labeled murine CD1d
tetramer pre-loaded with PBS57 (NIH Tetramer Core Facility,
Atlanta, GA, USA) was used to detect iNKT cells according to
the manufacturer’s instructions. Streptavidin PERCP-Cy5.5 was
obtained from BD Pharmingen and streptavidin PE-Cy5 from
eBioscience. For intracellular staining with IFN-γ and IL-17,
cells were made permeable with an intracellular staining buffer
(eBioscience). Anti-IFN-γ-PE (Clone XMG1.2, BD Pharmingen)
or anti-IFN-γFITC (XMG1.2; eBioscience), and anti-IL-17-APC
(Clone TC11-18H10.1, BioLegend) were used for intracytoplasmic
staining.
KIDNEY HISTOLOGY AND URINE ASSAYS
Kidneys were fixed with 4% formalin (PBS), dehydrated, and
embedded in paraffin. All sections were counterstained with Gill’s
hematoxylin (Panreac, Spain), dehydrated with graded alcohol
and xylene, and mounted with DPX (VWR International, Radnor,
PA, USA). To evaluate IgG-immunocomplex deposits on kidneys,
snap-frozen spleens in OCT media (Sakura Finetek Europe B.V.,
The Netherlands) were cryosectioned (5µm), blocked with 6%
FCS in PBS,and stained with alexa 488-conjugated anti-mouse IgG
(Life Technologies Corporation, Invitrogen, Paisley, UK). Images
were analyzed using a Nikon Optiphot-2 microscope (Nikon) and
acquired with a high-definition color camera (Nikon).
Freshly voided urine samples were tested for proteinuria
using Albustix (Siemens Healthcare Diagnostics Inc. Tarrytown,
NY, USA).
IN VITRO CELL ACTIVATION
Splenic lymphocytes were activated with plate-bound anti-CD3
(2µg/ml) (145-2C11; BD Pharmingen) combined with purified
soluble anti-CD28 (1µg/ml) (37.51; BD Pharmingen). Spleno-
cytes (100,000 cells/well) were cultured in RPMI 1640 medium
supplemented with 10% FBS,100 IU/ml of penicillin,100µg/ml of
streptomycin, and 2.5µM of β-mercaptoethanol in a 96-well plate
and activated. Supernatants were collected after 72 h of incubation
and IFN-γ levels were measured by ELISA. Additionally, after 24 h
of activation, cells were collected and the percentages of activa-
tion markers (CD25, CD40L) were analyzed by flow cytometry.
Th17 cell polarization was carried out according to BioLegend’s
protocol. Briefly, single splenocyte suspensions were activated
with 2µg/ml of plate-bound anti-CD3 (clone 145-11; BioLe-
gend), anti-CD28 (5µg/ml; clone 37.51, BD Pharmingen), TGF-
β1 (1 ng/ml, BioLegend), anti-IFN-γ (10µg/ml; clone XMG1.2,
BD Pharmingen), anti-IL-4 (10µg/ml; clone 11B11; BioLegend),
IL-6 (50 ng/ml, Immunotools), and IL-23 (5 ng/ml, BioLegend)
over 3 days. Cells were then stimulated for 4–5 h with phorbol
myristate acetate (PMA; 50 ng/ml; Sigma-Aldrich) and ionomycin
(750 ng/ml; Sigma-Aldrich) in the presence of GolgiStop at 1:1500
(Pharmingen).
MEASUREMENT OF CYTOKINES
The amounts of IFN-γ in sera or in cell-culture supernatants were
evaluated with commercially available ELISA kits (R&D Systems).
Intracellular analysis of cytokines produced by CD4+ and CD8+
T cells, and iNKT cells was carried out by FACS analysis.
Spleen CD4+ T cells were isolated by using MACS CD4+ T-
cell Isolation Kit II (Miltenyi Biotec), following manufacturer’s
protocol. Cells were stimulated for 4–5 h with PMA (50 ng/ml),
ionomycin (750 ng/ml), and GolgiStop at 1:1500. APC-conjugated
anti-CD3 (eBioscience), pacific blue-conjugated anti-CD4 (BioLe-
gend), PE-Cy7-conjugated anti-CD8 (BioLegend), pacific blue-
conjugated anti-B220 (BioLegend), and PE-conjugated tetramer-
PBS57 (NIH) were used for flow cytometry staining. Cells
were then fixed and permeabilized with Foxp3 Staining Buffer
(eBioscience) before intracellular staining with alexa fluor
647-conjugated anti-IL-17 (clone TC11-18H10.1; BioLegend),
phycoerythrin-conjugated anti-IFN-γ (XMG1.2; BD Pharmin-
gen) or FITC-conjugated anti-IFN-γ (XMG1.2; eBioscience), IL-4
PE-Cy7 (11B11; BD Pharmingen).
IN VITRO PROLIFERATION AND VIABILITY ASSAYS
Splenocytes were resuspended in PBS with 5% FCS (106 cells/mL),
and stained with CFSE (Invitrogen) (1µL CFSE for each 106 cells),
during 5 min at room temperature. Then cells were washed with
cold PBS with 5% FCS and with cold PBS. After the second wash,
lymphocytes were resuspended in RPMI media (10% FCS, and
2.5µM β-mercaptoethanol). Cells were stimulated with 10µg/mL
F(ab′)2 anti-mouse IgM (Jackson ImmunoResearch), or complete
media as a negative control.
In order to measure viability, lymphocytes were stained with
fluorochrome-labeled antibodies against surface antigens using
standard methods. Cells were washed twice in azide-free and
serum/protein-free PBS, and stained with Live/Dead Fixable far
Red (Invitrogen) following manufacturer’s protocol. Then lym-
phocytes were stained with eFluor 450-conjugated Annexin V
eBioscience during 15 min at room temperature, and washed with
RPMI media. Proliferation and viability were assessed 72 h later.
STATISTICS
Mann–Whitney tests were used to calculate p values for all
numeric data.
RESULTS
Ly9-DEFICIENT MICE DEVELOP SPONTANEOUS AUTOIMMUNITY
To assess the role of Ly9 in humoral autoimmune responses, Ly9-
deficient mice were generated by mutated 129-derived ES cells
(29) and backcrossed with B6 (C57BL/6) or BALB/c mice for 12
generations. First, we analyzed the presence of ANA in sera of 3,
6, 9, and 12 months old Ly9−/−(B6.129) mice by immunofluores-
cence staining of Hep-2 cells. As shown in Figures 1A,B, an age-
associated increase in ANA titers was detected in Ly9−/− (B6.129)
mice that was significantly higher than those of their age-matched
Ly9+/+ (wild-type; wt) counterparts. The differences in ANA
serum levels between wt and Ly9−/− mice were statistically sig-
nificant as early as 3 months of age. At 12 months of age, 80%
of the serum samples from Ly9−/−(B6.129) showed ANA titers
≥1:4096. In contrast, 100% of the serum titers from their wt
counterparts measured ≤1:512. Further analysis demonstrated
that by age 12 months Ly9−/−(B6.129) mice displayed significant
increases in their circulating levels of anti-double-stranded (ds)
DNA and anti-nucleosome IgG antibodies in comparison to their
wt counterparts (Figures 1C,D).
In order to further dissect the role of Ly9 in the humoral
autoimmune response, excluding any effects stemming from
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FIGURE 1 | Autoantibody development in Ly9−/−(B6.129) mice. (A)
Determination of anti-nuclear autoantibody (ANA) titers in the serum from
Ly9+/+ (wt) and Ly9−/− mice obtained at the indicated time points, and as
described in Section “Materials and Methods.” (B) Representative
immunofluorescence image of permeabilized Hep-2 incubated with sera
from 1-year-old wt as compared with 1-year-old Ly9−/− mice (sera dilution
1:600). After washing, IgG was detected with anti-mouse IgG-Texas Red
(red). Nucleus was stained with DAPI (blue). (C) ELISA was performed to
assess autoantibodies against double-stranded DNA (dsDNA) and (D)
nucleosome in serum from 12-month-old wt and Ly9−/− mice (see Materials
and Methods). Experiments were initially conducted with a total of n=11
B6 (wt) and n=11 Ly9−/−(B6.129) female mice. Small horizontal bars
indicate the mean. Statistical significances are shown.
epistatic interactions, we determined autoantibodies in the serum
of Ly9−/−(BALB/c.129) mice. Once again, an age-associated
increase in ANA titers was also detected in Ly9−/−(BALB/c.129)
mice that was significantly higher than those of their age-
matched wt counterparts. As was observed in the B6 back-
ground mice, the differences in ANA serum levels between
wt and Ly9−/−(BALB/c.129) mice were statistically significant
as early as 3 months of age, reaching its highest level at age
12 months when 91.6% of Ly9−/−(BALB/c.129) mice presented
ANA titers ≥1:256 compared with 72.7% of their wt coun-
terparts whose titers measured ≤1:64 (Figures 2A,B). Notably,
ANA titers in Ly9−/−(B6.129) mice were always higher than
those of Ly9−/−(BALB/c.129) at the evaluated time points,
most likely due to the additional effect of the epistatic inter-
actions, which induced spontaneous loss of immune toler-
ance to nuclear antigens (25). Comparable levels of anti-
dsDNA and anti-nucleosome were detected on Ly9-deficient
mice from both genetic backgrounds (Figures 2C,D and
Figures 1C,D), although Ly9−/−(B6.129) mice displayed much
FIGURE 2 | Spontaneous humoral autoimmune response in
Ly9−/−(BALB/c.129) mice. (A) ANA titers in the serum of 3- to
12-month-old Ly9+/+ (wt) and Ly9−/− mice. (B) Representative
immunofluorescence staining of permeabilized Hep-2 incubated with sera
from 1-year-old wt as compared with 1-year-old Ly9−/− mice (sera dilution
1:200). After washing, IgG was detected with anti-mouse IgG-Texas Red
(red). Nucleus was stained with DAPI (blue). (C) Determination by ELISA of
autoantibodies against double-stranded DNA (dsDNA) and (D) nucleosome
in serum from 12-month-old wt and Ly9−/− mice. Experiments were initially
conducted with a total of n=11 BALB/c (wt) and n=15 Ly9−/−(BALB/c.129)
female mice. Small horizontal bars indicate the mean. Statistical
significances are shown.
higher ANA titers. This likely reflects the presence of pref-
erential nuclear antigen recognition based on genetic back-
ground, which has been also observed in other lupus mod-
els (31).
Ly9-deficient mice exhibited a significant increase in IgG2b
(Figure 3A) as well as higher ratios of IgG2a, 2b, and IgG3 isotypes
vs. IgG1 than wt mice. Due to the high titers of autoantibodies
observed on aged Ly9-deficient mice sera, we further investi-
gated the presence of alterations in these animals’ renal physi-
ology and functionality. Twelve-month-old Ly9−/−(BALB/c.129)
mice did not exhibit proteinuria (Figure 3B) or differences in
their glomeruli morphology compared to their wt counterparts.
Although we observed a mild increase in IgG-immunocomplex
deposits in Ly9-deficient mice (Figure 3C), this initial trait
prior to any sign of glomerulonephritis did not trigger a renal
pathology.
In summary, our findings reveal that the absence of the
Ly9 receptor per se initiates the progressive development of
autoantibodies, independently of any epistatic interactions.
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FIGURE 3 | One-year-old Ly9−/−(BALB/c.129) mice showed a skewed IgG
isotype and no renal pathology. (A) Indicated IgG isotypes were analyzed
in sera from 12-month-old Ly9−/−(BALB/c.129) and wt mice. (B) Protein was
measured with a colorimetric dipstick in fresh urine samples from
12-month-old mice. (C) Representative immunohistology (IH) image (Gill’s
hematoxylin) of paraffin-embedded kidney sections (upper panels) and
IgG-immunocomplex image detected by immunofluorescence (bottom
panels) of cryopreserved kidney sections from 12-month-old wt (n=4) and
Ly9−/− (n=4) mice. Horizontal bars represent the mean level. SEM and
statistical significance are shown.
Ly9−/− AGED MICE EXHIBITED SPLENOMEGALY AND ALTERED KEY
CELL SUBSETS RELATED TO SELF-TOLERANCE
The role of Ly9 as an inhibitor molecule in the development
of spontaneous autoimmunity, excluding any effects dictated
by epistatic interactions, is further supported by the obser-
vation that 12-month-old Ly9−/−(BALB/c.129) mice exhibited
splenomegaly, which is a feature often present in SLE-prone
mice (32, 33). The mean and SEM of spleen weight in wt
(n= 7) and Ly9−/−(BALB/c.129) mice (n= 11) were 95.53± 3.40
and 147.7± 10.36 mg, respectively (p= 0.0021). Consistently, an
increase of 75.8% in Ly9−/−(BALB/c.129) spleen cell numbers,
compared with wt spleens, was observed (Figures 4A,B).
A deeper analysis of cell subsets by flow cytometry
demonstrated altered B- and T-cell peripheral homeostasis in
Ly9-deficient mice. We first inspected the B-cell signature of the
disease in 12-month-old Ly9−/−(BALB/c.129) mice (Table 1).
Notably, the most significant difference was found in GC B cells,
with a percentage of 0.64± 0.19 in wt and 1.28± 0.30 in Ly9-
deficient mice (p= 0.0004), which was also evident due the strik-
ing expansion of GC cell numbers (Figure 4C and Table 1).
Although a major percentage of GC was observed in Ly9-deficient
mice, only a slight decrease in the percentage of Follicular B cells
was detected: 88.39± 3.15 (Ly9+/+) and 78.01± 7.25 (Ly9−/−),
which is indicative of follicular B-cell areas with a major pro-
portion of GC B cells. Transitional 1 (T1) B cells in wt and
Ly9−/−(BALB/c.129) mice showed percentages of 4.48± 1.08 and
9.47± 3.12, respectively. Marginal zone (MZ) B cells from Ly9-
deficient mice also showed increased percentages: 4.54± 1.78
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FIGURE 4 | Ly9 ablation alters key peripheral B andT subsets
implicated in autoimmunity. (A) Representative picture of spleens from
12-month-old wt (n=7) and Ly9−/−(BALB/c.129) (n=11); weight mean and
SEM are shown. (B) Spleen cellularity was determined. (C) Splenocytes
were stained with anti-B220 and anti-GL7 mAbs to calculate the
percentages and total cell numbers in the germinal center (GC) B cell
compartment, (D) or stained with anti-CD3, anti-CD4, anti-PD1, and
anti-CXCR5 to analyze Tfh cells. Horizontal bars represent the mean level.
SEM and statistical significances are shown.
(Ly9+/+) and 8.70± 2.97 (Ly9−/−) (Table 1). Thus, the pre-
viously mentioned B-cell subsets, most of them involved in
autoimmune diseases (34, 35), showed a near twofold percentage
increase in Ly9−/−(BALB/c.129) mice compared to their control
counterparts.
No altered proportion was found in the studied peritoneal B-
cell subsets from the 12-month-old mice (data not shown). Our
data also revealed a slightly increased frequency in the occurrence
of the most immature B-cell lineages, multipotent progenitor
(MMP) and Pro-B cells in the bone marrow of Ly9-deficient mice
(data not shown), which is a variation that has been observed in
other lupus-prone mice (36).
In examining the T-cell signature of Ly9 deficiency-mediated
autoimmunity, the most remarkable difference we observed was
in Tfh cells, which showed a threefold percentage increase and cell
number expansion (Figure 4D). Importantly, excessive Tfh-cell
numbers have been linked to a positive-selection defect in GC,
which would account for such differences in the autoantibody
generation (21). As previously mentioned, Ly9-deficient mice also
exhibited higher ratios of IgG2a,b and IgG3 isotypes vs. IgG1,
suggesting that the peripheral tolerance checkpoint that controls
GC and Tfh cells becomes altered by the absence of Ly9 mole-
cule (Figure 3A). In the Ly9-deficient spleen, we found a slight
increase in the ratios occurring between CD4+ and CD8+ T cells.
We also observed an increase in effector CD4+ and CD8+ T-cell
subsets, although it was not significant. Interestingly, the iNKT
cell pools in these animals were also enlarged: 3.53± 1.23% wt
and 7.67± 2.80% Ly9−/− mice (Table 1).
We conclude that Ly9 gene ablation in a BALB/c background
results in the disturbance of B and T cell subsets involved in
autoimmunity, with major differences occurring in both Tfh cells
and GC B cells.
Ly9 RECEPTOR MODULATES IFN-γ SECRETION BY CD4+ T CELLS
To determine the lymphocyte subsets that facilitate the ignition
of SLE-related pathology in the absence of Ly9, we searched
for any altered peripheral cell populations in 8- to 12-week-old
Ly9−/−(BALB/c.129) mice. Slight differences were observed in the
T-splenic compartment with a small increase in percentage of
CD4+ T and iNKT. Notably, most of the alterations were displayed
by B-cell subsets, with Transitional T1 B cells presenting the major
difference (Table 2). A deeper examination of T1 and MZ B cells
including IgM as a cell marker (T1:CD23− CD21− IgM+, MZ:
CD23− CD21+ IgM+) (37) demonstrates that Ly9-deficient mice
possessed approximately a threefold increase of T1 subset and also
an expanded MZ B subset (Figure S1 in Supplementary Mater-
ial). Based on these results, we conclude that Ly9-deficiency alters
the development of B-cell subsets which may be involved in the
generation of autoantibodies.
Abnormalities in BCR signaling could shape the splenic B-cell
populations and predispose to autoimmune disease. Therefore,
we assessed the proliferation and survival of splenic B cell from
Ly9−/− mice after IgM stimulation. The proliferation and apop-
totic responses of Ly9-deficient B cells were similar to those
observed in the wt B cells, with the exception of a slight decrease
in percentage of late apoptotic cells in the Ly9-deficient mice
(Figure 5).
Since earlier studies have demonstrate the critical implication
of SLAMF receptors in Th1/Th2/Th17 polarization (14, 26, 38),
we hypothesized that Ly9-deficient splenocytes in 8- to 12-week-
old mice would foster an alteration in T-cell cytokine production
prior to disease onset, thereby enabling autoantibody production
at older ages. First, we asked whether the ablation of murine Ly9
could modulate IL-17 secretion by CD4+ T cells under Th17 polar-
izing conditions, since earlier reports have implicated the human
Ly9 receptor in IL-17 T-cell secretion (38, 39). No significant
differences were detected in the percentage of IL-17 secreting
CD4+ T cells (Figure 6A). On the other hand, our group has pre-
viously shown that monoclonal antibodies against Ly9 negatively
regulate TCR signaling, thereby inhibiting ERK phosphorylation
and IFN-γ secretion (26, 40). Herein, we investigated the role of
Ly9 in IFN-γ modulation by activating splenic T cells with anti-
CD3 and anti-CD28. A significant increase in IFN-γ secretion,
as well as an increase in the expression of CD40L in CD4+ T
cells was detected in the absence of Ly9 compared with wt cells
(Figures 6B,C). A similar result was obtained when evaluating the
expression of the CD25 activation marker (data not shown). In
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Table 1 | Flow cytometry analysis of B- andT-splenic cell subsets from 12-month-old wt and Ly9−/−(BALB/c.129) mice.
Parental Subset Marker Ly9+/+ Ly9−/−
B-CELL LINEAGE
B220+ T1 B220+CD21−CD23− 4.48±1.08 ** 9.47±3.12
Follicular-B B220+CD21+CD23high 88.39±3.15 ** 78.01±7.25
MZ-B B220+CD21+CD23−/low 4.54±1.78 ** 8.70±2.97
Lymphocytes GC B cells B220+GL7+ 0.64±0.19 *** 1.28±0.30
Lymphocytes Plasma B cells B220−/low CD138+ 0.19±0.03 0.24±0.03
T- AND NK-CELL LINEAGE
CD3+ CD4 SP CD4+CD8− 73.55±4.00 76.65±5.56
CD8 SP CD4+CD8+ 21.03±4.08 16.28±3.2
CD4+ Effector CD4 CD3+CD4+ CD8− 42.87±4.26 50.50±10.01
CD44highCD62Llow
CD8+ Effector CD8 CD3+CD8+CD4− 17.53±12.18 35.27±15.02
CD44highCD62Llow
CD4+ Reg T cells CD3+CD4++CD25+ 17.16±1.62 20.10±15.02
Tfh CD3+CD4+PD1+ 3.27±1.10 *** 9.90±3.09
CXCR5+
Tefh CD4++CD44highCD62Llow 3.06±1.42 5.29±2.00
CXCR5−PSGL-1−
Lymphocytes iNKT B220−CD3+ 3.53±1.23 ** 7.67±2.8
CD1d Tetr+
CD3− NK CD3−DX5+ 3.55±1.02 3.60±0.74
T1, transitional 1 B cells; MZ-B, marginal zone B cells; GC B cells, germinal center B cells; SP, single positive; Reg, regulatory;Tfh, follicular helperT cells; iNKT, invariant
natural killer T cells; NK, natural killer; p-value significance; **p<0.001, ***p<0.0001. Results represent the mean±SEM of 7 wt and 11 Ly9−/−(BALB/c.129) mice
for each subset analyzed.
addition, PMA/ionomycin activation of splenic cells revealed that
Ly9-deficient mice foster CD4+ T, CD8+ T, and iNKT cells capable
of secreting major quantities of IFN-γ prior to the development of
autoimmunity (Figure 6D). Furthermore, isolated Ly9-deficient
CD4+ T cells consistently showed an increased IFN-γ produc-
tion after PMA/ionomycin activation as compared with wt mice
(Figure 6E). In contrast, no significant difference in percentage of
IL-4 producing CD4+ T cells was observed (data not shown). In
accordance with these results, 12-month-old Ly9−/−(BALB/c.129)
mice exhibited an increased percentage of IFN-γ producing CD4+
T cells,which correlated with the high ANA titers detected in serum
(Figure 6F). Nevertheless, we could not detect IFN-γ in the serum
of these mice (data not shown).
Thus, in the absence of the Ly9 molecule occurs an increase
in peripheral T and iNKT IFN-γ secretion, a key cytokine in the
pathogenesis of SLE which has been previously shown to trigger
the accumulation of pathogenic Tfh and GC B cells (41).
DISCUSSION
Despite extensive research, the mechanisms by which susceptibility
and effector genes initiate and promote autoantibody production
and tissue damage remain poorly defined. In the present study, we
have shown that Ly9 deficiency results in a spontaneous loss of tol-
erance, reflected principally in the development of autoantibodies,
a process which is thought to underlie the initiation of SLE
syndrome.
We first found that the absence of the Ly9 gene in mice
with a B6 and BALB/c background resulted in the develop-
ment of autoantibodies. The loss of tolerance to nuclear antigens
detected in Ly9−/−(B6.129) mice was reminiscent of those pre-
viously observed in B6.Sle1b and B6.129Chr1b congenic mouse
strains (6, 42). We found that Ly9−/−(B6.129) mice developed
autoantibodies as early as 12 weeks of age. In fact, by 9 months
of age all mice were autoantibody positive, a pattern similar to
that found in SLAMF receptor Slamf1-deficient (B6.129) mice
(25). Most SLAMF receptor-deficient mice have been generated
by altering those SLAMF genes located in chromosome 1 via the
homologous recombination of 129-derived embryogenic stem
cells (25, 29, 43, 44). Once the resultant mice are backcrossed
onto B6 mice [e.g., Slamf1−/−(B6.129)], the deficient mice are
affected by the epistatic interaction that occurs between the
129 gene segment and the B6 genome. Thus, epistatic inter-
actions between 129-derived and B6 genes in Ly9−/−(B6.129)
mice greatly contribute to the autoantibody response. Excep-
tionally, the disruption of the Ly108 gene in congenic mice
[Ly108−/−(B6.129)] mitigates the generation of autoantibodies,
indicating that SLAMF members carry out opposing functions
(e.g., Ly108 vs. Ly9).
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Table 2 | Flow cytometry analysis of B- andT-splenic cell subsets from 8- to 12-week-old wt and Ly9−/−(BALB/c.129) mice.
Parental Subset Marker Ly9+/+ Ly9−/−
B-CELL LINEAGE
B220+ T1 B220+CD21−CD23−/low 10.87±0.71 *** 15.18±0.46
Follicular-B B220+CD21+CD23high 79.96±0.84 *** 74.30±0.18
MZ B220+CD21+CD23−/low 4.76±0.21 * 5.79±0.31
Lymphocytes GC B cells B220+GL7+ 4.65±0.65 4.25±1.04
Lymphocytes Plasma B cells B220−/low CD138+ 0.27±0.06 0.22±0.08
T- AND NK-CELL LINEAGE
CD3+ CD4 SP CD4+CD8− 65.93±6.27 * 71.53±1.57
CD8 SP CD4−CD8+ 16.81±4.78 12.7±1.53
CD4+ Effector CD4 CD3+CD4+CD8− 28.58±1.66 29.80±1.13
CD44highCD62Llow
CD8+ Effector CD8 CD3+CD8+CD4− 7.50±2.80 8.26±1.55
CD44highCD62Llow
CD4+ Reg T cells CD3+CD4+CD25+ 8.77±1.22 9.33±0.76
Tfh CD3+CD4+PD1+ 3.40±0.44 3.55±0.54
CXCR5+
Lymphocytes iNKT B220−CD3+ 4.22±0.53 * 5.11±0.69
CD1d Tetr+
CD3− NK CD3−DX5+ 0.82±0.32 0.63±0.14
T1, transitional 1 B cells; MZ-B, marginal zone B cells; GC B, germinal center B cells; SP, single positive; Reg, regulatory; Tfh, follicular helper T cells; iNKT, invariant
natural killer T cells; NK, natural killer; p-value significance; *p<0.05, ***p<0.0001. Results represent the mean±SEM of wt and Ly9−/−(BALB/c.129) mice (n=5)
for each subset analyzed.
We next assessed the role of Ly9 in autoimmune disease
without the confounding influence of mixed haplotypes by uti-
lizing Ly9−/−(BALB/c.129) mice. Although autoantibody titers
were lower compared to Ly9−/−(B6.129) mice, this strain clearly
developed an autoimmune response based on the significant
increases of ANA, anti-dsDNA, and anti-chromatin antibodies
compared to their wt counterparts. By contrast, other SLAMF
receptor-deficiencies embedded in the BALB/c genome, such
as Slamf1−/−(BALB/c.129) and Slamf2−/−(BALB/c.129), do not
develop any autoimmune response (25), underscoring the role
played by Ly9 as a negative regulator in the pathogenesis of lupus.
Consequently, among the various SLAMF receptors, both Ly9 and
2B4 rise as unique factors contributing to the reinforcement of
tolerance (24).
As a consequence of breaching tolerance, a plethora of dis-
orders can develop a posteriori; e.g., T and B cells are reportedly
involved in the amplification and perpetuation of the autoimmune
response, resulting in inflammation and cytokine dysregulation
(45). This proved to be the case in our 12-month-old Ly9-deficient
mice in which various B and T cells subsets underwent alterations.
Notably, the most noteworthy differences in older mice were found
in Tfh and GC B cells, two cell types which have been shown to
preferentially express the Ly9 receptor (46).
In order to begin to understand why Ly9-deficient mice devel-
oped spontaneous autoimmunity, we search for any abnormal
peripheral B and T cell development prior to full autoantibody
disorder on 8- to 12-week-old Ly9-deficient mice. We observed
alterations in the B-cell splenic compartment, with the most
prominent expansion displayed by Ly9-deficient transitional T1 B
cells. Interestingly, SLE patients present increased numbers of T1
cells, although their role in lupus is still ill defined (35). In addition,
8- to 12-week-old Ly9-deficient mice displayed an increase in MZ
B cells. Even though many autoreactive antibodies appear to be
the product of GC reactions, major evidence begins to reveal that
MZ B cells play a key role in homeostasis and tolerance. Notably,
the MZ B-cell expansion has been directly implicated in lupus
pathogenesis in some murine models (47–50), but not others (51,
52). Autoimmunity mediated by B cell is usually linked to a B-
cell hyperresponse which change the B-cell splenic composition.
Thus, an increased BCR signal, as shown by mice deficiencies in
SHP-1, FcγRII, CD22, Cbl-b, or overexpressing CD19, leads to a
B-cell hyperresponsiveness upon BCR stimulation, change B-cell
subsets normal architecture, and culminates in a systemic autoim-
mune disease (53). Here, we show that there’s similar proliferation
and survival of Ly9-deficient B cells as compared with wt cells,
although we can not exclude the abnormal function of particular
B-cell subsets in the Ly9-deficient mice which could be the subject
of future investigations.
Next, we investigated how the absence of Ly9 could possi-
bly contribute to a cytokine imbalance prior to disease onset.
Others have shown that the engagement of human naive CD4+
T lymphocytes with an anti-human Ly9 monoclonal antibody
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FIGURE 5 | Ly9-deficient B cells displayed similar proliferation and
survival than wt cells after IgM stimulation. Splenic cells were obtained
from Ly9−/−(BALB/c.129) (n=4) or wt (n=4) mice and stimulated with
anti-IgM antibody during 72 h. (A) The cells were labeled with CFSE. Flow
cytometry analysis of gated B220+ cells was performed. The percentages
of B cells in each division are shown. (B) Apoptosis assay on gated B220+
cells was assessed by flow cytometry. The cells were stained with
Live/dead fixable far red and Annexin V eFluor 450. Quantification of the
data is presented in a bar diagram (Alive; Live/dead− Annexin V−, early
apoptotic; Live/dead− Annexin V+, late apoptotic; Live/dead+ Annexin V+,
necrotic; Live/dead+ Annexin V−). (A,B) are representatives of two
independent experiments.
under Th17 polarizing conditions results in an increase in IL-
17 (38, 39). No alterations in IL-17 producing T lymphocytes
were observed once Ly9-deficient mice splenic cells were acti-
vated under Th17 polarizing conditions. Previous reports showed
a diminishing IL-4 production and no altered IFN-γ secretion
by Ly9-deficient CD4 T cells (29). In contrast, in the absence of
Ly9, we observed an increase in IFN-γ producing T cells with
no significant alteration in IL-4 secretion. Importantly, IFN-γ has
long been associated with lupus (54). This apparent contradic-
tion could be explained by the influence of epistatic interactions
as well as the mice background, since previous studies were per-
formed in Ly9−/− with a mixed background (B6× 129) mice.
Recent reports have demonstrated that the overproduction of
IFN-γ induces an aberrant accumulation of Tfh and GC cells
(41).We also found that these subsets underwent expansion in
Ly9-deficient mice, when the influence of confounding epistatic
interactions was absent. These observations suggest that the Ly9
FIGURE 6 | Ly9-deficient mice foster skewed IFN-γ producingT and
iNKT cell populations prior to full disease onset. (A) Representative
dot plot histogram of IFN-γ and IL-17 producing CD4+ T cells from
3-months-old Ly9−/−(BALB/c.129) or wt mice splenocytes after exposure
to Th17 polarizing conditions. Bar histograms show percentage of IL-17
and IFN-γ producing CD4+ T cells, respectively. (B) Amounts of IFN-γ in
the culture supernatants of 72 h anti-CD3 (2µg/ml) and anti-CD28
(1µg/ml) mAb-stimulated splenocytes as measured by ELISA (n=4 mice
per group). (C) Histogram of CD40L expression in CD4+ T cells after 24 h
activation, as judged by flow cytometry analysis (n=4 mice per group).
(D) Percentage of IFN-γ producing CD4+ and CD8+ T, and iNKT gated from
total splenocytes or (E) isolated splenic CD4+ T cells from 8- to
12-week-old Ly9−/−(BALB/c.129) or wt mice as analyzed by flow cytometry
after 4 h cell activation with PMA, ionomycin, and GolgiStop. (F)
Splenocytes from 1-year-old mice were activated with PMA, ionomycin,
and GolgiStop and then IL-17 and IFN-γ were analyzed by flow cytometry.
Bar histograms show the percentage of CD4+ T cells producing IL-17 and
IFN-γ. Correlation between ANA titers and percentage of IFN-γ producing
CD4+ T cells is represented in a distribution histogram; dotted line
represents mean of ANA titers+ (2×) standard deviation (SD) or mean
percentage of IFN-γ producing CD4+ T cells+ (2×) SD from wt mice.
Horizontal bars represent the mean level. Statistical significances are
shown. Data from (A,D,E) are representative of two independent
experiments. Data from (B,C) are representative of three independent
experiments.
molecule may play an inhibitory role in the expansion of these
subsets. In addition, Ly9-deficient mice showed a skewed isotype
switching toward IgG2a/b, an isotype induced by a Th1 response
that requires T cell-stimulated B lymphocytes. Although IgG2a
antibodies are the most pathogenic class of immunoglobulin (55,
www.frontiersin.org July 2013 | Volume 4 | Article 225 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
de Salort et al. Ly9 receptor mitigates autoimmune responses
56), we did not observe any major kidney pathology. However,
a mild increase in IgG-immunocomplex deposits was detected
in Ly9-deficient mice, a stage that often precedes full-blown kid-
ney pathology. Thus, an Ly9 mutation confers a predisposition to
autoantibody generation, but one that may require additional fac-
tors (e.g., a viral infection or additional gene alterations) before a
full lupus disease pathogenesis becomes evident. In addition, we
cannot exclude the influence of Ly9-deficient iNKT cells, a popu-
lation that underwent expansion in 8- to 12-week-old Ly9−/−mice
(30), on the observed autoimmune response. Although iNKT cells
generally play a tolerogenic role in autoimmunity, some mod-
els, and depending on the mouse strain and treatment protocol
used, iNKT cell activation exacerbates rather than protects against
autoimmunity (57), e.g., the stimulation of iNKT cells triggers
a Th1 immune response in adult NZB/W mice, resulting in the
exacerbation of systemic autoimmunity (58). Thus, iNKT dis-
ease protection is associated with enhanced Th2 and/or reduced
Th1 responses against targeted antigens. A deeper study of Ly9-
deficient iNKT cell will be needed to determine the specific role of
this cell-type in the observed autoimmune phenotype.
In summary, the data presented in this study sheds light on
the inhibitory function of the Ly9 cell-surface receptor, sug-
gesting that this molecule is involved in the maintenance of
peripheral cell tolerance by serving as a negative regulator of
the immune response. Further investigation will be required to
elucidate the precise mechanism by which Ly9 confers protec-
tion from autoimmunity. Nonetheless, this study demonstrates
that Ly9 may not only prove to be a valuable target for the treat-
ment of autoimmunity, but may also help build a more rational
road map toward understanding the molecular causes of SLE
syndrome.
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Figure S1 | SplenicT1 and MZ cells are expanded in Ly9−/−(BALB/c.129)
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cells as well as (C) MZ- and T1-B cells cellularity per spleen are shown. SEM and
statistical significances are shown.
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